Wegovy vs Mounjaro vs Zepbound in Bangkok: 2026 prices, supply, and which to pick

Three branded GLP-1 pens are available through Bangkok's private clinic and hospital network in May 2026: Wegovy (semaglutide), Mounjaro (tirzepatide), and Zepbound (tirzepatide for the obesity indication, distinct branding). Different active molecules in two cases, different brand positioning across all three, and meaningfully different price + supply profiles per channel.

This post is the side-by-side. What's actually in stock, what each costs at the premium-hospital tier and the mid-tier clinic tier, and the picking question once you have the numbers.

What each one is

• Wegovy · semaglutide branded for chronic weight management. Same molecule as Ozempic (which is branded for type-2 diabetes). 2.4mg once-weekly maintenance dose. STEP trials show ~15% body-weight reduction at 68 weeks.
• Mounjaro · tirzepatide branded for type-2 diabetes. Dual GIP and GLP-1 agonist. Doses from 2.5mg to 15mg once-weekly. Eli Lilly product.
• Zepbound · tirzepatide branded for chronic weight management. Same molecule and dose ladder as Mounjaro, different label and indication. Eli Lilly product. SURMOUNT trials show ~20.9% body-weight reduction at 72 weeks at the 15mg dose.

In Thailand, both Mounjaro and Zepbound carry tirzepatide. Clinical-effect-wise they are interchangeable. Brand positioning differs · Mounjaro is the long-established name and the one most clinics stock; Zepbound launched later in the global market and Thai distribution has been thinner. The Wegovy + Mounjaro pair is the practical decision most Bangkok-resident expats face.

What's actually in stock, May 2026

Medication	Premium hospitals	Mid-tier clinics

| Wegovy (2.4mg) | Stable across BNH, Bumrungrad, Samitivej, BDMS Wellness | Stable at Healthi Life, Boston Health Longevity, Fresh Genetiq | | Mounjaro (2.5mg → 15mg) | Stable, Thai-FDA-approved May 2025 (Zuellig Pharma distribution) | Stable, with occasional sub-step gaps | | Zepbound (2.5mg → 15mg) | Limited stocking · Bumrungrad and Samitivej carry, others typically substitute Mounjaro | Rare · most mid-tier clinics route to Mounjaro for tirzepatide | | Ozempic (semaglutide diabetes label) | Stable across all premium hospitals | Stable across mid-tier |

If a clinic does not stock the specific brand you ask for, the substitution they offer reveals their channel posture. A premium hospital that says "we have Mounjaro instead of Zepbound, same molecule" is being honest. A clinic that says "we have something equivalent" without naming what is signaling channel-clarity below where we route.

Per-month USD pricing, May 2026

Premium hospitals run 1.4 to 2x the mid-tier on the same dose. Insurance coverage varies (international plans more often cover obesity-indication pens than diabetes-indication, and BNH is the most insurance-friendly of the BKK premium tier).

Medication	Premium hospital	Mid-tier clinic

| Wegovy 2.4mg | USD 580 to 920 | USD 320 to 560 | | Mounjaro 5mg | USD 380 to 620 | USD 220 to 380 | | Mounjaro 10mg | USD 480 to 780 | USD 280 to 460 | | Mounjaro 15mg | USD 580 to 880 | USD 340 to 520 | | Zepbound 5mg | USD 420 to 680 (limited stock) | USD 280 to 420 (limited stock) | | Ozempic 1.0mg | USD 280 to 460 | USD 180 to 280 |

Numbers normalized from the public price pages of the Bangkok premium-hospital comparison vendors and the mid-tier clinics in our /vendor catalog. Consult fees at premium hospitals add USD 30 to 150 per visit; mid-tier clinics typically include the consult.

The picking question

Cost is one signal. The two other things to weigh:

Tolerability. Tirzepatide (Mounjaro/Zepbound) has more efficacy than semaglutide (Wegovy/Ozempic) but also more GI side effect surface area at high doses. Patients new to the GLP-1 class often tolerate Wegovy 2.4mg better than Mounjaro 10mg+ because the dose-step is shallower. The matchmaker accounts for urgency and budget signals · users picking "ready" + "full optimization" usually route to Mounjaro at higher doses; users picking "researched" + "meaningful" usually route to Wegovy or Mounjaro at lower doses.

Long-term continuity. SURMOUNT-4 + STEP-5 both show that stopping the drug returns weight in most patients. If you anticipate this is a long-term protocol, the per-month cost compounded over 12 to 36 months matters more than the cheaper-this-month answer. Mid-tier clinics with a 12-month relationship often beat premium hospitals on lifetime cost despite the same per-pen price.

Cross-region resupply. If you split time between Bangkok and another expat market, the medication that is easiest to refill at your other locations matters. Mounjaro is the most globally-distributed of the three; Wegovy is widely available across EU and UK; Zepbound is currently US-primary. The Bangkok-hop playbook covers the cross-border math for expats elsewhere in SE Asia.

What we recommend

For most Bangkok-resident expats new to the class with a body-weight reduction goal: start with Mounjaro at the mid-tier clinic, escalate slowly through the dose ladder, plateau at whichever dose gets you the result with tolerable side effects. Wegovy is the right pick if you are GLP-1-class-naive and want a shallower dose ramp. Zepbound is the right pick if you specifically want the obesity-indication label (matters for some insurance plans + some employer benefits in the US, less so in Thailand).

The matchmaker at /quiz routes by your goal cluster, region, and budget. The recommended vendor will have the 11-signal rubric breakdown on its scorecard so you can read the per-signal context before transacting. The premium-hospital comparison at /blog/bangkok-premium-hospitals-glp1-2026 goes deeper on Bumrungrad vs Samitivej vs BNH vs BDMS Wellness if your route is the JCI-anchored tier.